The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments have been game-changers for lung cancer and skin cancer, prostate cancer ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...

The average age of men who get diagnosed is 67.

At 77 years old, Tyson Johnson has been in treatment for metastatic prostate cancer for more than 20 years. “I’m the healthiest dead man you’ve ever seen,” the Carthage resident said jokingly as he ...

A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...

Florida State University researchers are working on new approaches to deciphering genetic data that may lead to new, more targeted prostate cancer treatments. Prostate cancer, which affects one in ...